• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

Introduction to (4-Aminopyrimidin-2-yl)methanol (CAS No. 1780700-09-5)

(4-Aminopyrimidin-2-yl)methanol (CAS No. 1780700-09-5) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various applications, particularly in the development of novel therapeutic agents.

The molecular structure of (4-Aminopyrimidin-2-yl)methanol consists of a pyrimidine ring with an amino group at the 4-position and a hydroxymethyl group at the 2-position. The presence of these functional groups imparts distinct chemical properties, making it a valuable intermediate in the synthesis of more complex molecules. Recent studies have highlighted its role in modulating biological pathways and its potential as a lead compound for drug discovery.

In the realm of medicinal chemistry, (4-Aminopyrimidin-2-yl)methanol has been explored for its ability to interact with specific protein targets. One notable application is its use as a scaffold for the development of inhibitors targeting kinases, which are key enzymes involved in cell signaling and proliferation. Kinase inhibitors have shown great promise in treating various cancers and inflammatory diseases, and the unique structure of (4-Aminopyrimidin-2-yl)methanol provides a promising starting point for optimizing these inhibitors.

Recent research has also focused on the pharmacological properties of (4-Aminopyrimidin-2-yl)methanol. Studies have demonstrated its ability to cross the blood-brain barrier, making it a potential candidate for central nervous system (CNS) disorders. This property is particularly valuable for developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's disease, where crossing the blood-brain barrier is a critical challenge.

The synthetic accessibility of (4-Aminopyrimidin-2-yl)methanol has further enhanced its appeal in pharmaceutical research. Various synthetic routes have been developed to efficiently produce this compound, ensuring its availability for large-scale studies and clinical trials. One common approach involves the reaction of 4-chloropyrimidine with an appropriate amine followed by methylation to introduce the hydroxymethyl group. These synthetic methods are well-documented and can be adapted to produce derivatives with enhanced biological activity.

In addition to its direct applications, (4-Aminopyrimidin-2-yl)methanol serves as a valuable building block in combinatorial chemistry. Its modular structure allows for the introduction of diverse functional groups, enabling the rapid generation of large libraries of compounds for high-throughput screening. This approach has been instrumental in identifying novel hits and leads for further optimization.

The safety profile of (4-Aminopyrimidin-2-yl)methanol is another important consideration in its development as a pharmaceutical agent. Preclinical studies have shown that it exhibits low toxicity and good metabolic stability, which are crucial factors for successful drug development. However, ongoing research is necessary to fully understand its pharmacokinetic properties and potential side effects.

Recent advancements in computational chemistry have also contributed to the understanding of (4-Aminopyrimidin-2-yl)methanol. Molecular dynamics simulations and quantum mechanical calculations have provided insights into its conformational flexibility and binding interactions with target proteins. These computational tools are invaluable for rational drug design and optimizing lead compounds.

In conclusion, (4-Aminopyrimidin-2-yl)methanol (CAS No. 1780700-09-5) is a promising compound with a wide range of applications in medicinal chemistry and pharmaceutical research. Its unique structural features, synthetic accessibility, and favorable pharmacological properties make it an attractive candidate for developing novel therapeutic agents. Ongoing research continues to uncover new opportunities for this versatile compound, solidifying its importance in the field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)